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Abstract. Poly(ADP-ribose) polymerase-1 (PARP1) activation contributes to the cascade of events initiated by amyloid-
(A) peptide eventually leading to cell death in Alzheimer’s disease brain. A significant accumulation of PAR polymers and
increase of PARP1 expression were detected in the cortex at the early (3.5 months) and intermediate (6 months) stage of
A deposition in the TgCRND8 mouse model. Our previous data highlighted the beneficial effects of oleuropein aglycone
(OLE), the main polyphenol found in the olive oil, against neurodegeneration both in cultured cells and in model organisms.
Here we found that 8-week OLE treatment (50 mg/kg of diet) to 6-month-old TgCRND8 mice rescued to control values
PARP1 activation and the levels of its product, PAR. In N2a neuroblastoma cells, PARP1 activation and PAR formation
upon exposure to N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) were abolished by pretreatment for 24 h with either OLE
(100M) or PARP inhibitors. A significant reduction of the NAD+ content, compared to controls, was found in N2a cells
exposed to MNNG (100M) for 90 min; the latter was slightly attenuated by cell treatment for 24 h with PJ-34 or with OLE.
In vitro and in vivo, the OLE-induced reduction of PARP1 activation was paralleled by the overexpression of Sirtuin1 (SIRT1),
and, in vivo, by a decrease of NF-B and the pro-apoptotic marker p53. In N2a cells, we also found that OLE potentiates the
MNNG-induced increase of Beclin1 levels. In conclusion, our data show that OLE treatment counteracts neuronal damage
through modulation of the PARP1-SIRT1 interplay.
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INTRODUCTION
Alzheimer’s disease (AD) is the most com-
mon form of dementia presently affecting, in the
developed countries, an estimated 44 million aged
people that are expected to triple by 2050. The key
histopathological sign of AD is the diffuse presence
of intracellular tangles of aggregated hyperphospho-
rylated tau and of minute extracellular amyloid-
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(A) deposits found in senile plaques, around cere-
bral vessels, and close to dystrophic/degenerating
neurites. According to the amyloid cascade hypoth-
esis, plaque deposits are considered responsible for
the functional alterations and behavioral deficits that
characterize AD [1]. In the last 20 years, the interest
in deciphering the relationship between plaque bur-
den and neuronal death has increasingly focused on
the importance of the oligomeric pre-fibrillar assem-
blies originating at the onset of fibril growth, as the
main neurotoxic species [2].
In spite of its severity and the number of affected
people, AD is a disease still in search of an effective
therapy. Recent research has highlighted the poten-
tial therapeutic value against sporadic AD and other
age-associated neurodegenerative diseases of several
plant polyphenols, including resveratrol, quercetin,
curcumin, oleuropein, oleocanthal, and hydroxythy-
rosol. The latter three compounds are found in
the leaves and drupes of plants of the Oleaceae
family, notably the olive tree and its main prod-
uct, olive oil. Our previous data on neuroprotection
by oleuropein aglycone (OLE) in TgCRND8 mice,
a model of A deposition, showed a significant
reduction of A levels, plaque load, and neuroin-
flammation together with a remarkable increase of
the autophagic response in OLE-supplemented mice
with respect to normally-fed littermates. These mod-
ifications matched a very significant improvement in
cognition and memory in OLE-supplemented mice
[3, 4] and suggested modifications of the expression
levels of proteins involved in such processes, possibly
with epigenetic implications. Accumulating evidence
indicates that epigenetic deregulation of finely tuned
processes involved in gene expression (such as DNA
methylation, histone methylation, acetylation, and
phosphorylation) might be crucial both in age-related
memory impairment and in the pathogenesis of
neurodegenerative diseases [5]. Interestingly, abnor-
mal acetylation of histones is involved in learning
and memory and might be causally associated to
AD pathogenesis [6], also considering that histone
acetylation seems to ameliorate cognitive deficits in
AD animal models [7]. In line with this observa-
tions, we found in the cortex and hippocampus of
our TgCRND8 mice an increased expression of the
nuclear enzyme histone deacetylase 2 (HDAC2) and
a subsequent reduction in histone 3 and 4 acety-
lation, in agreement with data previously reported
in rats [7] and in AD patients [6]. Importantly, we
observed that these modifications were fully reverted
in OLE-supplemented Tg mice [4]. These data agree
with previous data indicating that polyphenols such
as resveratrol, quercetin, and catechins are able to
activate sirtuin 1 (SIRT1), a class III HDAC involved
in the pathogenesis of different chronic pathologies,
including neurodegenerative diseases [8].
SIRT1 activity requires NAD+, and the activation
of enzymes involved in the synthesis or consumption
of NAD+ plays an important role in the regula-
tion of SIRT1 activity [9, 10]. In addition to SIRT1,
many other enzymes require NAD+ as a substrate
and, among these, poly (ADP-ribose) polymerase-
1 (PARP1) plays a role in many processes related
to neurodegeneration [11]. The normal function of
PARP1 is the routine repair of DNA damage by
adding poly (ADP ribose) polymers in response to
a variety of cellular stresses by its ability to convert
NAD+ in chains of poly(ADP-ribose) (PAR) poly-
mers. Many additional functions of PARP1 have now
been demonstrated in biochemical and molecular sig-
naling [12]. In the CNS, PARP inhibition attenuates
injury in pathologies like cerebral ischemia, trauma,
and excitotoxicity demonstrating a central role of
PARP1 in these pathologies. In particular, progres-
sive DNA damage and increased PARP1 activity
in aging neurons eventually leads to programmed
neuronal death and loss of memory consolidation;
moreover, PARP1 has been implicated in age-related
memory deficits and dementia [13]. Many different
proteins, including PARP1 itself, the nuclear factor-
B (NF-B) and histones [14], are targets of the
poly(ADP-ribosyl)ation reaction. PARP1 has been
reported to play a dual role in cell survival and
necrosis via induction of autophagy and NAD+/ATP
depletion, respectively [15]. PARP1 is needed to
repair DNA lesions induced by reactive oxygen
species, but its expression and activity may increase
inflammation via upregulation of NF-B signaling
[16].
Exposure to environmental/genotoxic stresses
leads to NAD+ depletion upon concomitant decrease
of SIRT1 activity and PARP1 activation [17]. The
latter has been shown in different pathological con-
ditions [18], and the presence of PAR polymers has
been reported in postmortem brain samples [19], skin
fibroblasts, and lymphoblasts from AD patients [20].
Although the PARP1-AD relationship needs confir-
mation and mechanistic explanation, previous data
indicate that PARP1 activation mediates A-induced
neuronal death, and deletion or inhibition of PARP1
gene can markedly improve neuronal survival [18].
A crosstalk between SIRT1 and PARP1 does exist;
in fact, PARP1 can be acetylated and activated under
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stress conditions whereas PARP1 activity is blocked
following SIRT1-dependent deacetylation [21]. On
the other hand, PARP1 overactivation suppresses the
activity of SIRT1 by reducing cellular NAD+ lev-
els, suggesting that the two proteins might be able to
counterbalance each other’s activity thus controlling
the cell survival/cell death equilibrium [21].
Several studies have shown that olive polyphe-
nols affect antioxidant and anti-tumor and other cell
activities upon genetic modulation [22]. Here, we
sought to further stress the epigenetic correlates of
the OLE beneficial effects against neurodegeneration
by investigating the activation state of PARP1 and its
crosstalk with SIRT1 both in TgCRND8 mice and
in N2a cultured cells. In addition, since SIRT1 and
PARP1 modulate the activity of both NF-B and the
p53 tumor suppressor protein [23], we also investi-
gated whether the inhibition of the transcription of
these pro-inflammatory and pro-apoptotic proteins
by OLE could underlie the beneficial effects of this
polyphenol.
MATERIALS AND METHODS
Ethics statement
Transgenic CRND8 mice harboring a double-
mutant gene of APP695 [24] and wild type (wt)
control littermates were used following the ECC (DL
116/92, Directive 86/609/EEC) and National guide-
lines for animal care. The protocol was approved by
the Committee on the Ethics of Animal Experiments
of the Italian Ministry of Health (Permit Number:
152/2014-B).
Animals
4-month-old TgCRND8 and wt mice were used
(n= 6/group/genotype, equally divided for sex). The
mice were treated for 8 weeks with a modified low-fat
(5.0%) AIN-76A diet (10 g/day per mouse) com-
posed of 50.0% sucrose, 5.0% fat, 20.0% casein,
15.0% corn starch, 5.0% powdered cellulose, 3.5%
AIN-76 mineral mix, 1.0% AIN-76A vitamin mix,
0.3% DL-methionine, and 0.2% choline bitartrate
(Piccioni, Milan, Italy), either as such (untreated
mice) or supplemented with OLE (50 mg/kg of
diet) (OLE-fed mice), as recently reported [3, 4].
In addition, a group of 1.5-month-old OLE-treated
TgCRND8 mice and a group of untreated TgCRND8
or wt mice (n= 6/group/genotype, equally divided for
sex) was used for immunohistochemical and western
blotting analysis of PAR polymers only. Paraffin-
embedded brain slices of 6-month-old OLE-fed wt
mice [3] were employed for the analysis of PAR
immunoreactivity reported in Fig. 1.
Oleuropein deglycosylation
Oleuropein (Extrasynthase, Genay Cedex, France)
deglycosilation was performed according to Konno
et al. [25] with minor modifications [3]. Briefly, a
10 mM solution of glycated oleuropein in 0.1 M
sodium phosphate buffer, pH 7.0, was incubated with
7.55 I.U./mL of -glycosidase overnight at room
temperature in the dark. The reaction mixture was
centrifuged at 10,000 × g for 15 min to precipitate
the aglycone. The complete oleuropein deglycosyla-
tion was confirmed by assaying the glucose released
in the supernatant with the Glucose (HK) Assay
Kit (Sigma-Aldrich, Milan, Italy). GC-MS analysis
showed the absence of any oleuropein in the precip-
itate and the substantially total recover of OLE in
the same precipitate. A 50 or 100 mM OLE stock
solution in DMSO was stored protected from light;
the solution was diluted immediately before use in
seed oil (for mice feeding) or in buffer (for in vitro
experiments).
Cell treatments and western blotting analysis
N2a murine neuroblastoma cells (European Col-
lection of Authenticated Cell Cultures, ECACC) were
plated in Eagle’s minimum essential medium (MEM)
supplemented with non-essential amino acids, 10%
FCS (Sigma-Aldrich, Steinheim, Germany), antibi-
otics, and glutamine. The cells were maintained in
a 5.0% CO2 humidified atmosphere at 37◦C. To
induce protein poly-ADP-ribosylation, the cells were
incubated for 15 min with 100M of the PARP1
activator methylnitronitrosoguanidine (MNNG).
After treatment for 24 h with OLE (100M) or with
the PARP inhibitors 6(5H)-phenanthridinone (PHE,
30M) or N-(6-oxo-5,6-dihydrophenanthridin-2-
yl)-(N,N-dimethylamino) acetamide hydrochloride
(PJ-34, 20M), the cells were lysed in Laemmli
buffer (60 mM Tris–HCl, pH 6.8, 2% (w/v)
SDS, 10 mM EDTA, 10% (w/v) glycerol) and
protein concentration was determined with a
BCA detection kit (Pierce, USA). The samples
were added with −mercaptoethanol and bro-
mophenol blue, boiled for 10 min, clarified at
10,000 × g for 10 min, run on 8% SDS-PAGE,
and transferred to PVDF membranes (Amersham
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Fig. 1. OLE inhibits PARylation in TgCRND8 mice. A) Representative photomicrographs of PAR immunoreactivity in the cortex of 6-
month-old mice, note the high PAR immunoreactivity in the cortex of untreated TgCRND8 mice compared to OLE-fed Tg and wt mice. B)
Western blotting analysis of PAR protein levels in the cortex of 3.5- and 6-month-old untreated wt and Tg mice and OLE-fed Tg mice. C)
Double immunofluorescence with NeuN (red) and PAR (green) antibody and (D) with GFAP (red) and PAR (green) antibody plus DAPI
(blue). PAR immunoreactivity is mainly detected within the nucleus of neurons and in a few astrocytes GFAP positive in Tg mice only, as
shown in panels on the right (arrows). n= 5-6 mice/group. ∗p< 0.05 versus Tg mice.
GE Healthcare, Buckinghamshire, UK). After
blocking with 5.0% (w/v) BSA in 0.1% (v/v) PBS-
Tween-20, the membrane was incubated overnight
at 4◦C with specific primary antibodies (Abs)
(Table 1). After washing, the membranes were
incubated for 1.0 h with 1:10000 specific secondary
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Table 1
Antibodies employed in the study
Antibody Specific Dilution Antigen retrieval Host Source
WB IHC for IHC
Anti-Poly (ADP-ribose) [PAR] Poly(ADP-ribose) 1:1000 1:100 Citrate Buffer Mouse AdipoGen
Anti-Poly (ADP-ribose) [PAR] Poly(ADP-ribose) ND 1:200 Citrate Buffer Rabbit BD Pharmingen
PARP PARP-1 1:1000 ND Rabbit Cell Signaling
NeuN Neuronal Nuclei ND 1:200 Citrate Buffer Mouse Millipore
GFAP Glial fibrillary acidic protein ND 1:500 Rabbit Dako
Phospho-NF-B p65 (Ser536) Phospho-NF-B p65 (Ser536) 1:1000 1:100 Citrate Buffer Rabbit Cell Signaling
NF-B p65 NF-B p65 1:1000 ND Rabbit Cell Signaling
Phospho-p53 (Ser46) Phospho-p53 (Ser46) 1:1000 1:50 Citrate Buffer Rabbit Cell Signaling
p53 p53 1:500 ND Rabbit Santa Cruz
Beclin1 Beclin1 1:1000 ND Rabbit Abcam
SIRT1 SIRT1 1:400 ND Rabbit Proteintech
−actin −actin 1:1000 ND Mouse Santa Cruz
-tubulin (HRP-conjugated) -tubulin 1:5000 ND Mouse Proteintech
aa, amino acid, WB, western blot; IHC, immunohistochemistry, ND, not done.
goat anti-rabbit and goat anti-mouse Abs (Molecular
Probes, Life Technologies). The immunoreactive
bands were detected with the Immobilon Western
Chemiluminescent HRP substrate (Millipore, Bil-
lerica, MA, USA) and quantified by densitometric
analysis using a ChemiDoc system and the Quantity
One software (Bio-Rad Laboratories, Italy). 1:1000
mouse monoclonal anti--actin Ab (Santa Cruz
Biotechnology Inc.) was used for protein load
normalization.
N2a cell treatment and nucleotide measurement
N2a cells were plated in MEM, 10% FCS (FCS,
Sigma-Aldrich), antibiotics, and glutamine. The cells
were treated for 24 h with 100M OLE or with
100M OLE plus 100M MNNG (90 min). The
NAD+ levels were measured by means of an enzy-
matic cycling procedure according to [26]. Briefly,
the cells grown in a 48 well plate were killed with
50l of 1 N HClO4 and the mixture was neutral-
ized by adding an equal volume of 1 N KOH. Then,
100l of cells extract was added with 50 mM bicine
(50l) and mixed with an equal volume of bicine
buffer containing 23.0l/ml ethanol, 0.17 mg/ml
MTT, 0.57 mg/ml phenazine ethosulfate, and 20g
alcohol dehydrogenase. The mixture was left stand-
ing at room temperature for 10 min before absorbance
measurement at 550 nm.
Animal tissue processing
At the end of the treatment with OLE, the mice
(3.5- and 6-month-old) were sacrificed by cervical
dislocation and the brains were rapidly removed
and divided sagittally. For protein analysis, corti-
cal and hippocampal samples from one hemibrain
were immediately sectioned, snap-frozen and stored
at –80◦C. The other hemibrain was postfixed for 48 h
in phosphate-buffered 4.0% paraformaldehyde, pH
7.4, at 4◦C, rinsed in PBS and embedded in paraffin
for immunohistochemistry.
Immunohistochemistry and western blotting
Immunohistochemistry was performed on 5.0m
coronal paraffin-embedded sections, as previously
described [27]. The sections were incubated
overnight at 4◦C with the primary Ab (Table 1)
diluted in 0.1 M PBS, pH 7.4, containing 0.3% Triton
X-100 and 5.0 mg/mL BSA. On day 2, the sec-
tions were incubated for 1.0 h in the dark with the
appropriate fluorescent secondary Ab (Alexa Fluor
594- or 488- conjugated monoclonal anti-mouse and
polyclonal anti-rabbit Ab; Invitrogen, New York,
USA) diluted 1:400. For double immunostaining, the
sections were incubated overnight with the second
primary Ab in the dark at 4◦C and, on day 3, for
1.0 h at room temperature with the second fluorescent
Ab diluted 1:400 in BS. The analysis of nega-
tive controls (not treated with the primary Ab) was
simultaneously performed to exclude the presence
of non-specific immunofluorescence staining, cross-
immunostaining, or fluorescence bleed-through.
For western blotting analysis, tissue and cell
samples were homogenized in ice-cold RIPA lysis
buffer; then, 40g of proteins was applied to 4–12%
Criterion XT Bis-Tris Gel (Novex NuPAGE, Lyfe
Technologies, New York, USA) for electrophoresis
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with XT MOPS running buffer (Lyfe Technologies,
New York, USA). The separated proteins were trans-
ferred onto 0.2m nitrocellulose membrane by the
iBlot dry blotting system (Invitrogen, New York,
USA) and incubated overnight at 4◦C with the pri-
mary Ab (see Table 1). The day after, the blots were
incubated for 1.0 h with the HRP-conjugated sec-
ondary Ab (Thermo Scientific, Waltham, MA, USA)
diluted 1:4000 in BS. The immunocomplexes were
visualized by enhanced chemiluminescence (Amer-
sham ECL, GE Healthcare, Buckinghamshire, UK)
and acquired using the ImageQuant 350 system
(GE Healthcare, Buckinghamshire, UK). Densit-
ometric band analysis was performed using the
Image Quant TL software (GE Healthcare, Bucking-
hamshire, UK). The bands were normalized to the
respective housekeeping protein or to/ tubulin. All
concentrations of primary Ab were titrated to provide
optimal staining (Table 1).
Real-time PCR
Total RNA was isolated from wild type or trans-
genic mouse treated or not with OLE, as described
above, by the RNeasy mini kit (Qiagen, Germany),
subjected to RNase-free DNase digestion (Ambion,
USA) and analyzed spectroscopically. 1.0g of
RNA was retro-transcribed using iScript™ (Bio-
Rad, USA) and amplified with specific primers, as
described below. For mouse PARP1 mRNA: forward
5’-CACTCTGCACACGTCCTGGAGAAAG-3’,
reverse 5’-GGAGGGCATCTGCTCAAGTTTGTT
AC-3’; for 18S rRNA: forward 50-AAAACCAA
CCCGGTGAGCTCCCTC-30, reverse 50-CTCAGG
CTCCCTCTCCGGAATCG-30. All primers were
purchased from IDT (IDT, Germany). PCR ampli-
fication was performed by means of SSOADV
UNIVER SYBR SMX (Bio-Rad, USA) according to
manufacturer instruction. PCR amplification of 18S
rRNA was used as the normalizer. Real-time PCR
assays were performed using the Rotorgene 6000
cycler system (Qiagen, Germany).
Data analysis
Statistical analysis was performed using One
way ANOVA followed by Bonferroni post hoc test
and the significance was defined as p< 0.05. Data
are reported as mean ± standard error of the mean
(S.E.M).
RESULTS
Effects of OLE on PARP1 activation
in TgCRND8 mice
PARP1 activation generates PAR polymers [28].
Comparable PARP1 activity enhancement and PAR
accumulation have been reported in AD patients,
particularly in neurons of the frontal and tempo-
ral lobes [19], in the brain of transgenic TASTPM
AD mice [18] and in the hippocampus of 3-month-
old TgCRND8 mice [29]. Thus, we firstly searched
for the presence of PAR polymers in the frontal
cortex of untreated or OLE-fed 3.5- and 6-month-
old TgCRND8 or wt mice. Two age groups were
employed to assess whether PARylation occurred at
3.5 months of age, the early stage of A deposi-
tion [24] and/or at 6 months of age, the intermediate
stage of A deposition [3]. In both age groups,
PAR immunoreactivity was higher in the cortex of
TgCRND8 mice respect to wt mice, as exemplified
in 6-month-old animals, whereas PAR polymers were
markedly reduced in the cortex of 6-month-old OLE-
fed Tg mice with respect to untreated Tg mice of the
same age (Fig. 1A). The western blotting analysis
confirmed these data, showing a significant increase
in PAR polymer levels in the frontal cortex of 3.5-
and 6-month-old Tg animals compared to wt mice of
the same age (Fig. 1B), whereas in OLE-fed Tg ani-
mals of both ages PAR polymer levels were similar
to those found in wt mice.
Next, we sought to identify the type of cells
displaying accumulation of PAR polymers by dou-
ble immunofluorescence staining using antibodies
to NeuN (red) and to PAR (green) and antibod-
ies to GFAP (red) and to PAR (green) plus DAPI
(blue). In Tg and wt animals, PAR immunoreac-
tivity was found mainly within neuronal nuclei, as
shown by the positive staining with NeuN anti-
body plus DAPI (Fig. 1C), whereas it was also
detected within a few astrocytes only in Tg groups,
as shown by GFAP antibody staining (arrows in
the merged images of Fig. 1D). Notably, the num-
ber of PAR-immunopositive neurons detected in
TgCRND8 mice was strongly reduced in OLE-
fed Tg mice, confirming a possible inhibition of
PARP1 activation by OLE (Fig. 1C). Overall,
these data indicate that, in TgCRND8 mice, OLE
reduces PARP1 activation and PAR polymers to
the values found in wt mice, suggesting possible
protection against PAR accumulation also in AD
people.
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OLE inhibits MNNG-induced PARP1 activation
and attenuates NAD+ depletion in N2a cells
To confirm inhibition of PARP1 activation by
OLE in the mouse brain, we determined the levels
of PARylated proteins in cultured N2a neuroblas-
toma cells exposed for 15 min to 100M MNNG,
a PARP activator, in the absence or in the presence
of 100M OLE or of two PARP inhibitors (PHE,
30M or PJ-34, 20M) 24 h prior to treatment with
MNNG. As expected, we found that MNNG induced
a significant increase of PARylated proteins with
respect to untreated control cells (Fig. 2A). However,
the MNNG-induced PAR formation was markedly
reduced in cells treated with OLE, PHE, or PJ-34 24 h
prior to MNNG exposure, where PAR levels dropped
below control values. At the same conditions, cell
treatment with OLE, PHE, or PJ-34 alone did not
affect PAR formation.
PARP activity needs NAD+ as a substrate and
contributes to the modulation of intracellular NAD+
levels. Therefore, we measured NAD+ content in N2a
cells exposed to MNNG (100M) for 90 min to con-
firm the above reported data. At these conditions, we
found a significant reduction (–27%) of the NAD+
content as compared to the levels measured in control
cells. Such a reduction was slightly attenuated by cell
treatment for 24 h with 20M PJ-34 or with 100M
OLE (Fig. 2B). Treatment with OLE did not affect
NAD+ levels in control cells (not shown). Taken
together, these data indicate that OLE administra-
tion to cultured neuronal cells displays effects similar
to those elicited by PARP inhibitors contributing to
explain PAR decrease in OLE-fed Tg mice.
OLE reduces PARP1 expression and modulates
the PARP1-SIRT1 interplay in 6-month-old
TgCRND8 mice
Since PARP1 accounts for over 85% of nuclear
PARP activity [30], we next investigated PARP1
expression levels in 6-month-old Tg mice normally
fed or supplemented with OLE by determining
PARP1 mRNA levels. As expected, the PARP1
mRNA levels in the cortex of Tg mice were over 4
times higher than in the cortex of wt mice but were
fully rescued to those of wt mice upon OLE treat-
ment (Fig. 3A). These data matched those relative
to the PARP1 protein levels; in fact, in the cortex of
TgCRND8 mice we found a roughly 100% increase
of the 116 kDa PARP1 (the uncleaved protein) and
over a 100% increase of the 89 kDa PARP1 (the
caspase 3-cleaved fragment) as compared to wt mice
(Fig. 3B). However, in OLE-fed Tg mice the levels
of the 116 kDa and 89 kDa proteins were maintained
to the values found in wt mice. These data indicate
that, in our Tg model, diet supplementation with OLE
results in a significant decrease of PARP1 expression,
which explains both PARP1 activation reduction and
the lowered levels of PARylated proteins; they also
provide clues to explain OLE protection against apop-
totic cell death induced by PARP1 fragments generate
by caspase 3 [31].
A functional link between PARP1 and SIRT1 has
been reported, and previous data show that PARP1
activation with ensuing NAD+ reduction results in
SIRT1 inhibition [8]. Therefore, we investigated the
expression of SIRT1 in the cortex of our TgCRND8
mice, its co-localization with PARP1 and its modula-
tion by OLE. We found that SIRT1 immunoreactivity
was strongly reduced in the cortex of TgCRND8
mice as compared to wt mice and that, similarly
to the effect of other polyphenols [8], OLE treat-
ment increased its expression in Tg mice (Fig. 3C).
In line with the immunohistochemical data, quan-
titative analysis showed a significant reduction of
SIRT1 in Tg mice as compared to wt mice while
it appeared markedly increased in OLE-treated Tg
mice (Fig. 3D). Double labeling fluorescent immuno-
histochemistry with PARP1 (green) and SIRT1 (red)
antibodies plus DAPI (blue) revealed co-localization
between PARP1 and SIRT1 (Fig. 3E, yellow color)
in all groups of animals, irrespective of treatment
and genotype; however, as reported above for PAR,
PARP1 was expressed in Tg mice at higher levels
than in wt animals, whereas it expression was reduced
in OLE-treated mice. Altogether, these data indicate
that OLE treatment increases the expression of SIRT1
and reduces that of PARP1, confirming the ability of
this polyphenol to interfere with the functional link
between PARP1 and SIRT1.
OLE increases SIRT1expression in N2a cells
Our previous studies in TgCRND8 mice and in cul-
tured cells showed that OLE administration results in
the activation of the autophagy-lysosome system [3,
32] and decreases the expression of histone deacety-
lase 2 (HDAC2), with ensuing increase of histone
acetylation [4]. On the other hand, it is known that
polyphenols activate SIRT1 which, in turn, stimulates
autophagy and thereby mimics caloric restriction-
mediated lifespan extension [33]. It is also known
that PARP1, besides playing a role in cell death,
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Fig. 2. OLE inhibits PARP1 activation and attenuates NAD+ levels in N2a cells exposed to MNNG. N2a cells were exposed to MNNG
for 15 min then, PARylated proteins were detected by immunoblotting (A). MNNG-induced PARylation in inhibited by cell treatment with
OLE, PHE, or PJ-34 24 h prior to MNNG exposure. OLE, PHE, and PJ-34 treatment does not affect PARylated protein levels. B) NAD+
levels in N2a cells treated with MNNG for 90 min alone or in combination with PJ-34 or OLE, 24 h prior to MNNG exposure. A) ◦p< 0.05,
◦◦p< 0.01, and ◦◦◦p< 0.001 versus MNNG treated cells; ∗∗p< 0.01 versus controls. B) ∗p< 0.05 versus control cells.
can also induce cell survival via autophagy stimu-
lation [15]. Therefore, we investigated in N2a cells
(i) the effect on SIRT1 expression of cell treatment
for 24 h with 100M OLE (Fig. 4A) and (ii) the
effect on Beclin1, a protein involved in the initiation
and execution of autophagy, levels of cell treatment
with 100M MNNG for 15 min or of cell treat-
ment for 24 h with 100M OLE prior to exposure to
100M MNNG for 15 min (Fig. 4B). We found that,
in OLE-treated cells, SIRT1 levels were increased
by over 250%, as compared to control cells, and
that Beclin1 levels were increased by around 100%
upon MNNG exposure and by roughly 200% in
cells treated with OLE prior to MNNG exposure.
Altogether, these findings indicate that PARP1 acti-
vation by MNNG results in protein PARylation and
increased autophagy, in agreement with previous data
[34], and that OLE increases SIRT1 expression and
synergizes with MNNG as an autophagy trigger.
NF-κB expression is reduced in OLE-treated
TgCRND8 mice
PARP1 activation can influence brain injury and
neuronal death through modulation of the brain
inflammatory response; these effects are largely
mediated by its interactions with the nuclear tran-
scription factor NF-B [35, 36], whose abnormal
activation is involved in AD [37]. Therefore, in the
light of the anti-inflammatory activity of OLE previ-
ously reported [3, 38], we investigated in TgCRND8
mice whether a reduction of the phospho (p)-NF-
B, the protein form that migrates to the nucleus,
matched OLE-induced PARP1 inhibition. By double
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Fig. 3. OLE decreases PARP1 expression and increases SIRT1 expression in 6-month-old TgCRND8 mice. A) PARP1 mRNA levels and
(B) western blotting analysis of PARP1 protein levels in the cortex of 6-month-old OLE-fed Tg mice and untreated wt and Tg mice. C)
Immunofluorescence with SIRT1 (green) antibody plus DAPI (blue). SIRT1 immunoreactivity is localized mainly at perinuclear and nuclear
levels. D) Western blotting analysis of SIRT1 protein levels in OLE-fed Tg mice and untreated wt and Tg mice. E) Double immunofluorescence
with PARP1 (green) and SIRT1 (red) antibody plus DAPI (blue). n= 5-6 mice/group. A) ∗∗∗p< 0.001 versus Tg mice. B) ∗p< 0.05 versus
Tg mice. D) ∗∗p< 0.01 and ∗∗∗p< 0.001 versus OLE-fed Tg mice.
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Fig. 4. OLE promotes SIRT1 and Beclin1 expression in N2a cells. A) N2a cells were treated with 100M OLE for 24 h, then SIRT1
expression was detected by immunoblotting. B) Beclin1 protein levels in N2a cells exposed to 100M of OLE for 24 h plus MNNG 100M
for 15 min. A) ∗p< 0.05 OLE treated cells versus control cells; B) ∗p< 0.05 MNNG treated cells versus control cells; ∗∗∗p< 0.001 OLE +
MNNG-treated cells versus control cells; ◦p< 0.01 OLE + MNNG-treated cells versus MNNG-treated cells.
immunofluorescent staining with anti-p-NF-B (red)
and anti-PAR (green) Abs plus DAPI (blue), we found
that the high expression of p-NF-B, detected in the
cortex of 6-month-old TgCRND8 mice mainly at the
perinuclear and nuclear levels fully co-localized with
PAR-immunopositive polymers (Fig. 5A). However,
in OLE-fed TgCRND8 mice p-NF-B immunoreac-
tivity was drastically reduced and no, or very low,
p-NF-B immunoreactivity was detected, similarly
to the expression found in wt mice. The western
blotting quantitative analysis showed a significant
increase of p-NF-B in the cortex of TgCRND8 mice
as compared to wt mice, whereas it was significantly
reduced to the values of wt animals in OLE-treated
Tg mice (Fig. 5B), in agreement with the reported
anti-inflammatory effect of OLE.
OLE reduces p53 expression in the cortex
of 6-month-old TgCRND8 mice
PAR polymers are involved in both cell life and
death [28] and we found that the cleaved PARP1 89
kD pro-apoptotic fragment is increased in the cortex
of TgCRND8 mice (see Fig. 3B). Modifications of
the cellular levels of p53, a transcriptional activator
that senses cellular stresses and is up-regulated dur-
ing DNA damage, hypoxia and oxidative stress, have
been associated with neuronal damage both in in vivo
and in vitro models [39] as well as with neurode-
generative disorders [40]. p53 activation can lead to
either cell cycle arrest and DNA repair or to apoptosis
[41]. p53 is phosphorylated at multiple sites and its
phosphorylation at Ser46 regulates its pro-apoptotic
power [42]. We therefore investigated in TgCRND8
mice the relation, if any, between PARP, apoptosis
and phosphorylated p53 and any interference of OLE
administration with these processes.
In double immunofluorescence staining with both
p53 phosphorylated at Ser 46 (p53 S46) (red) and
PAR (green) Abs plus DAPI (blue) we found a strong
co-localization between PAR and p53 S46 immunore-
activity in the neurons of cortex of TgCRND8 mice,
as compared to wt mice (Fig. 6A). Remarkably,
the intense p53 S46 immunoreactivity and its co-
localization with PAR staining detected in TgCRND8
mice was significantly reduced in OLE-fed Tg mice.
These immunohistochemical data were confirmed by
the analysis of p53 S46 levels; in fact, we found that
the significant increase of p53 S46 levels detected
in the cortex of TgCRND8 mice respect to wt
mice, dropped to the wt values in OLE-fed Tg mice
(Fig. 6B). These findings indicate that in our mod-
els OLE protects neuronal cells against apoptosis by
interfering with the PARP/apoptosis/phosphorylated
p53 relation.
DISCUSSION
PARP1 activation contributes the cascade of events
initiated by A increase and aggregation eventually
culminating with neuronal cell death [18]; moreover,
in the AD brain it may represent, together with oxida-
tive stress, an early event in disease pathogenesis [19].
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Fig. 5. OLE reduces p-NF-B expression in 6-month-old TgCRND8 mice. A) Double immunofluorescence with p-NF-B (red) and PAR
(green) antibodies plus DAPI (blue). Note, the perinuclear and nuclear intense fluorescence of p-NF-B fully co-localizes with PAR polymers
in untreated TgCRND8 mice compared to untreated wt and OLE fed Tg mice. B) Western blotting analysis of p-NF-B levels versus total
NF-B levels in OLE-fed Tg mice and untreated wt and Tg mice. n= 5-6 mice/group. ∗p< 0.05 versus Tg mice.
Fig. 6. OLE reduces p53 S46 expression in 6-month-old TgCRND8 mice. A) Double immunofluorescence with p53 S46 (red) and PAR
(green) antibodies plus DAPI (blue). Note, in untreated TgCRND8 mice, an high number of immunopositive cells for p53 S46 Ab mainly
localized at perinuclear and nuclear levels and fully colocalized with PAR polymers, compared to untreated wt mice and OLE-fed Tg mice.
B) Western blotting analysis of p53 S46 protein levels versus total p53 levels in OLE-fed Tg mice and untreated wt and Tg mice. n= 5-6
mice/group ∗∗p< 0.01 versus Tg mice.
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PARP1 plays a critical role in keeping DNA integrity
and its increased activity in response to DNA dam-
age results in a significant reduction of NAD+ levels
[11]. A significant accumulation of PAR polymers
matching a significant increase of PARP1 activation
following its enhanced expression were detected in
the cortex of our transgenic CRND8 mouse model of
A deposition at the early (3.5 months) and interme-
diate (6 months) stage of A deposition. As already
reported in AD brain [19], we mostly found PAR and
PARP1 immunoreactivities within neurons and, lim-
ited to Tg mice, in a few astrocytes. However, OLE
treatment for 8 weeks of 6-month-old TgCRND8
mice rescued both PARP1 activation and the accumu-
lation of its product, PAR to the values found in wt
mice. In N2a neuroblastoma cells, PARP1 activation
and PAR formation induced by cell exposure to the
alkylating agent MNNG were abolished by 24 h pre-
treatment with either OLE or PARP inhibitors (PHE
and PJ-34). These data were confirmed by the deter-
mination of NAD+ levels in N2a cells exposed to
MNNG, either alone or in association with PJ-34 or
OLE; the data obtained with OLE led us to estab-
lish whether OLE could behave as an inhibitor of
PARP1. The significant reduction of NAD+ levels
by exposure of N2a cells to MNNG for 90 min (27%)
was not reverted significantly by cell treatment for
24 h with the PARP inhibitor PJ-34 (–20% n.s) nor
by OLE (–7%). This finding was likely due to the
existence of pleiotropic mechanisms affecting NAD+
levels. That OLE treatment resulted in a reduced ten-
dency to control NAD+ levels in MNNG-exposed
cells did not support our starting hypothesis that OLE
might be a direct inhibitor of PARP1. Accordingly,
in N2a cells, the lack of significant reversion by OLE
of the reduction of cellular NAD+ levels following
PARP1 activation by MNNG, likely reflected NAD+
utilization for OLE-induced SIRT1 activation. In fact,
OLE treatment enhanced SIRT1 expression both in
cultured cells and in Tg mice. Actually, the mod-
est reduction of PARP1 activation in OLE-treated
cells might be an indirect downstream event of the
increased SIRT1 expression induced by OLE, with
concomitant activation of autophagy, reduction of the
pro-inflammatory (NF-B) and pro-apoptotic (p53)
markers and decreased PARP1 activation [21]. In
turn, SIRT1 can suppress the activity of the PARP1
gene promoter, resulting in decreased PARP1 syn-
thesis which helps cells survival under mild stress
conditions [21]. By contrast, under severe stress con-
ditions, NAD+ depletion beyond a critical threshold
inhibits the activity of SIRT1, with hyperacetylation
of target proteins, including p53, Ku70, and PARP1,
eventually resulting in cell death [21].
Our previous studies both in vitro with cultured
cells [32] and in TgCRND8 mice [3, 38] together
with the present study in N2a cells indicate that
OLE is a strong activator of autophagy. Autophagy
is a basic mechanism to support cellular homeostasis
under stress conditions as well as a survival strat-
egy; however, autophagy can also be associated with
programmed cell death [43, 44]. Furthermore, it has
been reported that autophagy might be cytoprotec-
tive in response to DNA damaging agents and that
PARP1 activation is involved in the regulation of
this process [45]. Accordingly, we found that in N2a
cells the expression of Beclin1, an early autophago-
some marker, was increased by over 200% following
cell exposure to MNNG for 15 min, and markedly
increased by cell pretreatment with OLE for 24 h prior
to exposure to MNNG. The OLE-induced increase
of Beclin1 levels in N2a cells exposed to MNNG
might be related to the enhanced intracellular cal-
cium levels, as previously reported in cells treated
with MNNG [46] or with OLE [32]. Collectively,
our data indicate that PARP1 activation triggers both
the apoptotic and the autophagic machineries and
that only the latter is further stimulated by OLE
treatment. Interestingly, the pro-autophagic effects of
both MNNG and OLE apparently proceed through
AMPK [32, 34]. Moreover, since OLE increases
SIRT1 levels and autophagy is further increased
in cells exposed to MNNG plus OLE, our data
highlight SIRT1 activation as another mechanism
of autophagy stimulation by OLE in addition to
that previously reported proceeding both through
the Ca2+-CaMKK-AMPK-mTOR axis [32] and
through epigenetic mechanisms [4].
The crosstalk between PARP1 and SIRT1 suggest
that the increased activity of one protein might inter-
fere with the activity of the other [8]. Moreover,
PARP1 was shown to enhance the transcription of
NF-B activity, while SIRT1 was found to inhibit
NF-B activity [47, 48]. The functional activity
of p53, similarly to NF-B, has been shown to
be regulated oppositely by PARP1 and SIRT1 [49,
50]. Our experiments agree with this view, indicat-
ing that the activities of the two proteins are also
oppositely regulated by OLE. Thus, the increased
SIRT1 expression following OLE treatment might
underlie the decreased PARP1 expression and the
PARP1-mediated increases of NF-B and p53. As
far as the latter is concerned, SIRT1 activation
was found to interfere with the interaction between
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apoptosis-inducing factor (AIF) and p53 and to
favor deacetylation of the p53 C-terminal regula-
tory domain thus inhibiting its pro-apoptotic power
[8]. Notably, in our OLE-fed TgCRND8 mice we
found that the 89 kDa PARP1-cleaved protein was
significantly reduced respect to the levels found in wt
mice. Caspase-3 has been identified as a key media-
tor of programmed cell death in neurons; moreover,
PARP1 cleavage by caspase-3 is considered an hall-
mark of apoptosis and has been implicated in several
neurological diseases including cerebral ischemia,
AD, multiple sclerosis, Parkinson’s disease, trau-
matic brain injury, and others [31]. Accordingly, our
data lead to suggest that, in neuronal cells, OLE can
interfere inversely with the autophagic and the apop-
totic programs.
In conclusion, our in vitro and in vivo study high-
lights the existence of a complex interplay between
OLE, apoptosis, autophagy, SIRT1, and PARP1 activ-
ity. In particular, we here report for the first time
that, in addition to autophagy, OLE interferes with
the PARP1-mediated cascade of events leading both
to apoptotic neuronal cell death via p53, to the
inflammatory response via NF-B induction, and
to increased autophagy via increased SIRT1 activ-
ity, further favoring cell survival. These findings
implement and extend our previously reported data
providing a new mechanism of neuroprotection by
OLE with possible implications in AD.
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